Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
Gong Feng, Luca Valenti, Vincent Wai‐Sun Wong, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 46-56
Closed Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Current status and future trends of the global burden of MASLD
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 697-707
Closed Access | Times Cited: 169
MAFLD predicts cardiovascular disease risk better than MASLD
Ziyan Pan, Gamal Shiha, Gamal Esmat, et al.
Liver International (2024) Vol. 44, Iss. 7, pp. 1567-1574
Closed Access | Times Cited: 29
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus
Xufen Zeng, Krista A Varady, Xiangdong Wang, et al.
Metabolism (2024) Vol. 161, pp. 156028-156028
Closed Access | Times Cited: 18
An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease
Le Zhang, Mortada El‐Shabrawi, Louise A. Baur, et al.
Med (2024) Vol. 5, Iss. 7, pp. 797-815.e2
Closed Access | Times Cited: 16
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
Xiaodong Zhou, Seung Up Kim, Terry Cheuk‐Fung Yip, et al.
Gut (2024) Vol. 73, Iss. 11, pp. 1883-1892
Closed Access | Times Cited: 15
MAFLD as part of systemic metabolic dysregulation
Jing Zhao, Lu Liu, Yingying Cao, et al.
Hepatology International (2024) Vol. 18, Iss. S2, pp. 834-847
Closed Access | Times Cited: 14
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH
Liang Tao, Xinquan Yang, Chaodong Ge, et al.
Cell Metabolism (2024) Vol. 36, Iss. 10, pp. 2190-2206.e5
Open Access | Times Cited: 14
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
Harry Crane, Guy D. Eslick, Cameron Gofton, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 3, pp. 436-448
Open Access | Times Cited: 13
MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease
Ziyan Pan, Moutaz Derbala, Khalid Al‐Naamani, et al.
Annals of Hepatology (2024) Vol. 29, Iss. 5, pp. 101512-101512
Open Access | Times Cited: 13
Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
Yuxiao Jiang, Lili Wu, Xiaopeng Zhu, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 12
NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics
Dimitris Kounatidis, Natalia G. Vallianou, Eleni Geladari, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 826-826
Open Access | Times Cited: 11
Resmetirom for MASH patients with diabetes: challenges and opportunities in the real world
Li-You Lian, Giovanni Targher, Christopher D. Byrne, et al.
Metabolism (2024) Vol. 156, pp. 155935-155935
Closed Access | Times Cited: 11
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
Huai Zhang, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2024) Vol. 18, Iss. 4, pp. 1178-1201
Closed Access | Times Cited: 11
High‐Sensitivity C‐Reactive Protein Is Associated With Heart Failure Hospitalization in Patients With Metabolic Dysfunction‐Associated Fatty Liver Disease and Normal Left Ventricular Ejection Fraction Undergoing Coronary Angiography
Xiaodong Zhou, Qin‐Fen Chen, Giovanni Targher, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 10
Transketolase promotes MAFLD by limiting inosine-induced mitochondrial activity
Lingfeng Tong, Zhangbing Chen, Yangyang Li, et al.
Cell Metabolism (2024) Vol. 36, Iss. 5, pp. 1013-1029.e5
Closed Access | Times Cited: 10
Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study
Ana‐Lucia Mayén, Mirna Sabra, Elom K. Aglago, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti
Xie Wei, Jing Gan, Xiaodong Zhou, et al.
Cell Metabolism (2024) Vol. 36, Iss. 6, pp. 1269-1286.e9
Closed Access | Times Cited: 9
Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
Rutao Lin, Jianghua Zhou, Qinmei Sun, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 7, pp. 802-811
Closed Access | Times Cited: 8
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
Sumin Oh, Yang Hyun Baek, Sung‐Ju Jung, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 2, pp. 247-262
Open Access | Times Cited: 7
From HFpEF to “metabolic (dysfunction)-associated HFpEF”: Time to act
Xiaodong Zhou, Gregory Y.H. Lip, Ming‐Hua Zheng
Science Bulletin (2024) Vol. 69, Iss. 7, pp. 850-852
Closed Access | Times Cited: 7
Resmetirom for MASH-related cirrhosis
Gong Feng, Virginia Hernández‐Gea, Ming‐Hua Zheng
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 7, pp. 594-594
Closed Access | Times Cited: 6
Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study
Xiaodong Zhou, Cuifang Xu, Qin‐Fen Chen, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 9, pp. 3684-3695
Closed Access | Times Cited: 6
A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis
Xiang Zhang, Ming‐Hua Zheng, Dehua Liu, et al.
Cell Metabolism (2024)
Open Access | Times Cited: 6
Palm-Sized Wireless Transient Elastography System with Real-Time B-Mode Ultrasound Imaging Guidance: Toward Point-of-Care Liver Fibrosis Assessment
Zihao Huang, Like Wang, Shang-Yu Cai, et al.
Diagnostics (2024) Vol. 14, Iss. 2, pp. 189-189
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top